| Literature DB >> 26999048 |
Avi Z Rosenberg1, Michael D Armani2, Patricia A Fetsch3, Liqiang Xi4, Tina Thu Pham4, Mark Raffeld4, Yun Chen2,5, Neil O'Flaherty2, Rebecca Stussman2, Adele R Blackler2, Qiang Du2, Jeffrey C Hanson1, Mark J Roth3, Armando C Filie3, Michael H Roh6, Michael R Emmert-Buck2,7, Jason D Hipp1, Michael A Tangrea2,8.
Abstract
Precision medicine promises to enhance patient treatment through the use of emerging molecular technologies, including genomics, transcriptomics, and proteomics. However, current tools in surgical pathology lack the capability to efficiently isolate specific cell populations in complex tissues/tumors, which can confound molecular results. Expression microdissection (xMD) is an immuno-based cell/subcellular isolation tool that procures targets of interest from a cytological or histological specimen. In this study, we demonstrate the accuracy and precision of xMD by rapidly isolating immunostained targets, including cytokeratin AE1/AE3, p53, and estrogen receptor (ER) positive cells and nuclei from tissue sections. Other targets procured included green fluorescent protein (GFP) expressing fibroblasts, in situ hybridization positive Epstein-Barr virus nuclei, and silver stained fungi. In order to assess the effect on molecular data, xMD was utilized to isolate specific targets from a mixed population of cells where the targets constituted only 5% of the sample. Target enrichment from this admixed cell population prior to next-generation sequencing (NGS) produced a minimum 13-fold increase in mutation allele frequency detection. These data suggest a role for xMD in a wide range of molecular pathology studies, as well as in the clinical workflow for samples where tumor cell enrichment is needed, or for those with a relative paucity of target cells.Entities:
Mesh:
Year: 2016 PMID: 26999048 PMCID: PMC4801357 DOI: 10.1371/journal.pone.0151775
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Potential impact of manual dissection versus xMD on NGS data.
Fig 2xMD application: Global epithelial microdissection.
(A) a 1.25X digital image of the whole normal intestine specimen immunostained with cytokeratin AE1/AE3+ (B) a 1.25X digital image of the whole tissue following xMD, highlighting the degree of stained tissue procurement (C) a 1.25X digital image of the stained tissue bound to the xMD film (D-F) images of the before and after slide and film of the same specimen at higher (5x) magnification.
Fig 3xMD applications: Nuclear and novel stain-based microdissection.
(A) IHC stained p53+ nuclei from a section of metastatic colon carcinoma (B) IHC stained ER+ nuclei from a section of breast carcinoma (C) IHC stained GFP+ cells from a culture slide (D) EBER+ cells after EBV-EBER in situ hybridization (E) captured GMS+ Aspergillus fungal organisms.
Fig 4xMD improves depth of NGS coverage in admixed cell cytospins.
(A) Schematic image of the NGS workflow. xMD isolated targets were compared to manual macrodissection via NGS (B) Select variant evaluation of the 95% lymphoma (ST486)/5% lung carcinoma (A549) cell line specimens comparing manual macrodissection to xMD enrichment (C) Select variant evaluation of the 95% lymphoma (ST486)/5% melanoma (UACC.62) cell line specimens comparing manual macrodissection to xMD enrichment. ND = not detectable.
xMD impact on NGS data quality for highly penetrant disease variants.
| Sample | % of ≥Q20 Bases | Mapped Reads | Mean Depth | Gene | Frequency (%) |
|---|---|---|---|---|---|
| 100% ST486 | 88.3 | 551,287 | 2,183 | APC | 51.5 |
| TP53 | 57.8 | ||||
| TP53 | 51.7 | ||||
| TP53 | 48.9 | ||||
| 100% A549 | 91.4 | 823,069 | 3,794 | KRAS | 100 |
| STK11 | 100 | ||||
| TP53 | 96.7 | ||||
| 100% UACC.62 | 86.2 | 374,503 | 1,209 | BRAF | 47.1 |
| CDKN2A | 99.2 | ||||
| MET | 49.3 | ||||
| 5% UACC.62-95% ST486 (Macrodissected) | 86.9 | 661,917 | 2,872 | APC | 52.3 |
| BRAF | ND | ||||
| CDKN2A | 2.7 | ||||
| MET | ND | ||||
| TP53 | 59.4 | ||||
| TP53 | 47.9 | ||||
| TP53 | 49 | ||||
| 5% UACC.62-95% ST486 (xMD) | 87.5 | 544,533 | 2,301 | APC | ND |
| BRAF | 52.3 | ||||
| CDKN2A | 83.6 | ||||
| MET | 30.3 | ||||
| TP53 | 7.1 | ||||
| TP53 | 15.9 | ||||
| TP53 | 12.8 | ||||
| 5% A549-95% ST486 (Macrodissected) | 87.1 | 985,460 | 4,194 | APC | 46.6 |
| KRAS | 4.9 | ||||
| STK11 | 2.9 | ||||
| TP53 | 56 | ||||
| TP53 | 45.1 | ||||
| TP53 | 43.8 | ||||
| 5% A549-95% ST486 (xMD) | 87.5 | 543,246 | 1,988 | APC | 2.3 |
| KRAS | 67.4 | ||||
| STK11 | 45.4 | ||||
| TP53 | 78.3 | ||||
| TP53 | 5.2 | ||||
| TP53 | 7.3 |
Ion Torrent PGM Data of macrodissected versus xMD-dissected cytospins. The quality of the amplicon libraries is reflected in the percent ≥Q20 base, mapped reads and read depth. The gene and gene variants are listed. Frequency represents the percentage of reads for a particular amplicon with the variant of interest relative to the wild type variants.
1c.3949G>C (p.Glu1317Gln)
2c.215C>G (p.Pro72Arg)
3c.473G>A (p.Arg158His)
4c.715A>G (p.Asn239Asp)
5c.34G>A (p.Gly12Ser)
6c.109C>T (p.Gln37*)
7c.1799T>A (p.Val600Glu)
8c.242C>T (p.Pro81Leu)
9c.2975C>T (p.Thr992Ile)
ND = Not Detectable.